MedGen

ul. Wiktorii Wiedeńskiej 9A, 02-954 WARSZAWA Tel: 501 377 150, email: diagnostyka@medgen.pl

GENETIC TEST ORDER FORM WITH DECLARATION OF INFORMED CONSENT FOR THE NGS TESTING

To be completed by an adult patient or parent / legal guardian of a patient:

Patient surname and name:									
Patient ID number:									
Phone number:	Phone numb	Phone number:							
Email address:									
The genetic material collected from me or my child (check	k applying):								
□ blood □ tissue □ amniotic fluid □ trophoblast □ othe	r ()						
is going to be used for molecular diagnostics based on D	NA analysis for:								
name of Dotyczy badania WES (całoeksomowego): Proszę zaznaczyć rodzaj badania z poniższego wykazu:	the disease and pr	ocedure							
Procedure	CNV	MT-DNA	ONKO						
NGS-022W	-	•							
NGS-022W-STANDARD									
NGS-022W-SMALL									
NGS-SZYBKI-WES									
NGS-SZYBKI-WES-PRENAT	*								
NGS-WES-PRENAT	*								
■ analysis included in the test MT-	ned genetic disease. there is a risk of DNA deg amily is different, the obtai he collection of the molecu	A analysis s correlated with cancers gradation which is a natural pro-	netic test may be incorrect.						

- 5. If I / my child underwent a transfusion within 2 months before collecting the material for genetic testing, I will inform a MedGen staff about it. Failure to inform the MedGen staff about the performed transfusion within the last 2 months before performing genetic tests may result in obtaining an incorrect test result and may affect the interpretation of the obtained genetic test result.
- As a standard, the DNA sample is stored in the MedGen Laboratory DNA bank, which makes it possible to perform additional tests for the patient at any time.

I DO NOT AGREE TO STORAGE OF DNA AGREE TO STORAGE OF DNA

- 7. Obtaining a non-informative result (e.g. due to low-quality DNA, insufficient amount of DNA, which can be verified after carrying out the DNA amplification reaction) is not the basis for reimbursement of the cost for the test. The MedGen Laboratory makes every effort to minimize the risk of such a situation (e.g. by using the highest quality reagents), however, it is not possible to exclude such a situation.
- 8. For whole-exome (WES) and whole-genomic (WGS) tests: the analysis of the detected variants will concern a patient-specific gene panel, which will be designed according to medical indications. However, during the analysis, it is possible to detect known pathogenic mutations in other genes contained in the gene library preparation kit used, which may be important for the health of the patient or his relatives (e.g. being a carrier of genetic diseases with recessive mode of inheritance). In case of incidential findings, they will be described in the result, unless the patient does not consent to it.

	In case of disag	T AGR	EE TO A	NALYS	SE OF (GENES NO										ORT IN	ICIDEN	ΙΤΔΙ	FINDIN	IGS
	I have obtained Ombudsman (J significance of	d the in Journal	formatio of Laws	n referi	ed to in 17, item	Art. 9 see	c. 2 d	of the	Act of	Mar	ch 23,	2017	on t	he ri	ights of th	he pati	ent and	d the	Patien	's Rights
	ations for the ex																			
Has	a molecular	r test	been	ever	done	before?	lf	so,	pleas	e i	name	the	tar	get	disease	e and	d type	e o	f the	
	e genetically c																			with a
	Place and da	ite									;	Signa	ature	of p	oatient >	18. y.	o. /par	ent/	legal g	uardian
															nature of					•
	•																			
N	IFD C	FN	J																	
	Centrum Medy	yczne	•																	
Pat	ient Name a	and S	Surnan	ne:																
Pat	ient PESEL	. num	ber:																	
(here The and right for the data	e undersigned einafter: the "A basis for data genetic inforn to withdraw r he period of li , rectify it, dela ee to receive	Admin proce nation) my cor mitation ete or	istrator' ssing is and C sent at on of cla limit pro	b for the form of	ne purponsent. GmbH me. Pe ue to the	oose of go The recip , German ersonal dance de data co vell as the	enetipient ny (o ata w ontro	ic tests of nly to the test of	sting. F the dat he anyle proce I have lodge a	Proving the control of the control o	iding or WE nous (d unti right	data S / W genet il the to re	is vo VGS ic ra cons ques	test w d sent	tary, but ts) are th ata, with is revol e Admir	nece ne Adr nout p ked, a nistrate	essary ministre ersona and afte or to a	for (ator al da er su	genetic (perso ata). I h uch rev	testing nal data nave the ocation
Place	e and date					re of referr									of patient					uardian
															of minor p					
How	do you knov	w abou	ut our l	aborat	tory?															
	web browser				docto	or				frier	nd				them	ed we	ebpage	Э		
	Facebook) othe	r:														
							ΔU	ITH	ORIZA	TIO	N									
												umb	or.							
1,	Patient / leg					ame	,	WILI	ıuler	LJ	CL II	umb	œi							••••••
auth	orize access	to me	edical i	nforma	ation:															
						n			surnar											
resi	ding in																			

contact phone number	
	Patient / legal guardian name and surname, date
authorize access to medical documentation:	
residing in	name and surname of the authorized person
	Patient / legal guardian name and surname, date
I do not authorize any person to access medica	al information or medical documentation.
	Patient / legal guardian name and surname, date

Based on the Regulation of the Minister of Health of 09/11/2015 on the types and scope of medical documentation and the method of its processing (Journal of Laws of 2015, No. 2069).